Stallergenes Greer : Résultat 2018 en phase avec les dernières indications - Guidances 2019 un peu au-dessus de nos attentes - OPA à 37 € d'Ares – Apporter à l’offre
>Rebond de l'EBITDA : résultats conformes - L’EBITDA 2018 s’élève à 40,2 M€, en hausse de 84%. L’EBITDA ajusté s’élève à 43.3 M€ contre 24.4 M€. L’EBIT est en ligne avec nos attentes à 17.6 M€ (vs 17.9 M€e) contre -5.4 M€ en 2017. Le RN ressort désormais positif à 12.8 M€ (vs 11.5 M€e) vs -9.9 M€ en 2017Des guidances au-dessus des attentes du CS - En première lecture, on fera observer que:1- le niveau d'EBITDA est en phase avec la fourchette de l...Stallergenes Greer is engaged in providing a comprehensive approach to allergies diseases, offering allergy specialists a range of products from diagnosis to sublingual and subcutaneous allergen immunothreaphy medicines. Co. portfolio comprises of four product categories; Sublingual products include ORALAIR® and STALORAL®; Subcutaneous products include ALUSTAL®, PHOSTAL®, ALYOSTAL ® and ALBEY®, and GREER EXTRACTS®; Veteninary product is a range of USDA-approved bulk extracts for animals suffering from a range of allergies; and Other products offer a variety of diagnostic tools and source materials in useful formulations for allergy specialists and physicians.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.